Life Sciences Archive » December, 2015

Life Sciences - December, 2015

249 articles

• Life Sciences Legislation And Regulation To Watch In 2016
• Life Sciences Cases To Watch In 2016
• 'Unicorn' Tech Co.'s $200M Deal Leads Pipeline Of 4 IPOs
• Fed. Circ. Won't Rethink $4M IP Verdict Against Globus
• Injunction On 'Gray Market' Abbott Diabetes Test Strips Grows
• 3 Things To Expect From Legal Tech In The New Year
• SAC To Pay $10M To End Investors' Trading-Fraud Suit
• Transport Cos. Can't Sink AXA's Suit Over $9M Drug Theft
• Del. Justices Uphold $195M Award To PharmAthene
• Canada Says Lilly Seeks 'Uber-Tribunal' In $500M IP Fight
• Valeant Faces Contact Lens Antitrust Class Action
• Actavis Says Namenda Product-Hopping Suit Has No Hop
• Generic Paxil Flap Ends Without Explanation
• Pelvic Mesh Plaintiff Wants $1.2M Ethicon Win Restored
• Novartis Unit Settles Sex Bias Suit For $8M
• Genelux Avoids Contempt Ruling In Chancery For Now
• Trade Groups Back Warner Chilcott In 3rd Circ. Doryx Row
• Kentucky AG Settles OxyContin, Risperdal Suits For $39.5M
• A Concession For ACA Medical Device Tax Opponents
• What To Know About Patent Reform Bills Heading Into 2016
• Celgene Allows Earlier Cancer Drug Generic In Patent Deal
• Judge Signs Off On $9M Skelaxin Antitrust Settlement
• Drug Cos. Ask 3rd Circ. To Halt Trial For Class Cert. Fight
• Boston Scientific Can't Get Fees From Blank Rome DQ
• Deals Rumor Mill: Shire, Caverion, ConocoPhillips
• Consumers Seek To Pause Pfizer Exit From Testosterone Suit
• Physician Assistant Gets 42 Months In Test-Referral Scheme
• Novartis Seeks Too Much In Attys' Fees In IP Row, NPE Says
• Supplement Co. Says Rivals' Products Use Steroid-Like Drugs
• Robbins Geller Looks To Lead Valeant Securities Fraud Suit
• Kaye Scholer Atty Charged In Shkreli Case Can Go To Cancun
• FDA Warning Wire: Sun Pharma, Device Changes, Food Filth
• New Evidence Backs Experts In Fixodent MDL, Consumers Say
• Ex-Oriole Can't Nix Insider Trading Evidence At 9th Circ.
• Ex-Steris Worker Backs Out Of Tainted Goods Suit
• In Congress: A Year-End Review
• Fosamax Users Rip Merck's Fracture Warnings In 3rd Circ.
• J&J Tagged With $7M Punitives In Pa. Pelvic Mesh Case
• FCA In 2015: 10 Qui Tam Highlights From The Past Year
• A Look At Martin Shkreli's Legal Woes
• The Role Of Previously Considered Prior Art In Instituting IPR
• Planting The Seeds For IP Protection Of Marijuana Brands
• Calif. Judge Transfers Teva Painkiller Suits To Kentucky
• Deals Rumor Mill: Lyft, Dermapharm, Greybull Capital
• Feds Urge High Court To Nix Enhanced Patent Damages Test
• Genelux Founder Pushes Chancery To Find Co. In Contempt
• Disputed IP Rights Properly Awarded To Biotech Co.: Judge
• Mass. Hospital Operator Slaps Rival With Monopoly Suit
• Group Says Aveeno 'Natural' Label Common In False Ad Suit
• Martin Shkreli Fired From KaloBios Post, Sued By Investors
• Walgreens Pushes Lipitor Pay-For-Delay Row At 3rd Circ.
• J&J Found Liable In 1st Philly Pelvic Mesh Case
• OrbiMed Launches $950M Venture Capital Fund
• The Firms That Dominated In 2015
• Law360 Names Practice Groups Of The Year
• Why All US Attorneys Should Read Justice Breyer's New Book
• Merck Ruling A Wake-Up Call For Patent Owners Facing PTAB
• Warner Chilcott To Pay $23M To End Calif. Fraud Claims
• Risperdal Victim Asks Pa. Judge For New Damages Trial
• Shkreli Leaves Turing Pharma As New CEO Tapped
• 10th Circ. Denies Marijuana Co. Appeal Of Tax Info Order
• Pfizer Should Face Lipitor Row In Calif., 3rd Circ. Hears
• Deals Rumor Mill: Syngenta, First Quantum, Apollo Global
• NJ Court Won't Ax Ironridge Global Suit Over Pharma Stocks
• Pharma Groups Urge Justices To Revive $18M Fine In IP Row
• Kaye Scholer Follows Crisis Blueprint After Lawyer's Arrest
• Consumers In Aveeno 'Natural' False Ad Suit Seek Cert.
• PTAB Shuts Down Another Bass AIA Review Of Horizon Drug
• FTC Tells High Court To Nix Boehringer's Appeal In Doc Row
• Axinn Veltrop Adds IP Attys From Arent Fox, Par Pharma
• Weight Loss Drug Maker Latest To Pull IPO Amid Weak Market
• Plastic Microbead Ban Heads To Obama For Signature
• Whistleblower Sues Hearing Aid Nonprofit After Being Fired
• Genzyme Asks Fed. Circ. To Revive Muscle Treatment Patents
• Allergan Wins Stay Of Infringement Suit Pending Patent Review
• Ex-Warner Chilcott Exec Prods Feds For Witness Info
• Senate Passes $1.8T Spending And Tax Extender Package
• The 13 Hottest Patent Law Issues Of 2015
• Shkreli, Kaye Scholer Atty Give Gov't Gift Of Shady Emails
• Warner Chilcott Defends Dismissal Of Doryx Case In 3rd Circ.
• Mylan, Ranbaxy Can't Halt Pay-For-Delay Suits Pending Appeal
• Kaye Scholer Atty, Shkreli May Not Enjoy Privilege For Long
• Merck Can't Save Patents In 1st Fed Circ. Pharma AIA Appeal
• BigLaw's Latest Bad Boy Built Colorful Career On Bitcoin
• Endo Health Faces Consumer Suit Over Flouride Labeling
• Jurors Prepare To Mull First Philly Pelvic Mesh Case
• Fla. High Court OKs Medical Marijuana Ballot Initiative
• AstraZeneca To Pay $4B For Cancer Treatment Developer
• The Biggest NJ Decisions From The Second Half Of 2015
• House Passes Sweeping $622B Tax Extenders Bill
• Amarin, FDA Off-Label Promotion Suit Stayed Until Feb.
• Pharma Bad Boy Martin Shkreli, Kaye Scholer Partner Arrested
• Calls For Bigger Patent Awards 'Disastrous,' Justices Told
• Endo Pays $39M To End Whistleblower's Fluoride Tablet Suit
• How Much Control Of Your Contracts Do You Really Have?
• Smith & Nephew Hip Implant Suit Survives Some Preemption
• NJ Plavix Suit Stayed Pending Supreme Court FCA Ruling
• Anda Not Covered In Drug 'Epidemic' Suit, 11th Circ. Told
• Purdue Takes Another Shot At Amneal Over OxyContin Generic
• Impossibility Preemption Possible For Brand-Name Drugs
• Lawmakers Reach Deal On Massive Tax Benefits Package
• Provigil Buyers' Per Se Theory Nixed In Pay-For-Delay Row
• Orrick Lands Weil Gotshal Life Sciences Ace In NY
• Acorda Blasts Bass-Backed Group's Bid To Nix Drug Patents
• SIGA Strikes PharmAthene Deal, Files Ch. 11 Plan
• Fla. Med. Marijuana Amendment Marches Toward 2016 Ballot
• Par Pharma Can't Get 2nd Fed. Circ. Win Over AIDS Drug
• Bio-Rad Denied Quick Appeal In Whistleblower GC's Suit
• UK Watchdog Probes OTC Pain Medicine Ads
• Allergan Loses Latest Bid To Nix Botox Price-Fixing Suit
• Supplement Co. Faces Sanctions Bid In Wal-Mart False Ad Row
• Customers Lose Cert. Bid In Lead-Laced Supplement Row
• FDA Warning Wire: Compounders, Supplements, Dirty Cheese
• Deals Rumor Mill: ChemChina, Saks Fifth Ave., Advance Auto
• Enzymotec Can't Shake Shareholder Suit Over $70M IPO
• Pacira Settles With FDA Over Pain Drug's Off-Label Uses
• DC Circ. Questions If $460M Czech Arbitration Row Is Moot
• 3 Things Baby Boomers Can't Stand About Young Lawyers
• Shoddy Hemorrhoid Stapler Sticks J&J Unit With $80M Verdict
• FTC To Get Its Mitts On AbbVie Docs In Pay-For-Delay Suit
• 7 Deadly Business Mistakes That Can Tank Your Law Practice
• Judge Unsure Whether To Remand Cherokees' Risperdal Suit
• Lifewatch Disclaims Telemarketing Scam At Trial With FTC
• Fla. Cannabis Growers Challenge Licensing Decisions
• NJ Plant Workers Hit Merck With FLSA Class Action
• Janssen Sued Over Diabetes Drug's Blood Disorder Risk
• Insys Blasts Coalition's Bid To Invalidate Painkiller Patents
• 3M Warming Device Infection Suits Grouped In Minn.
• Hyland's Says False Advertising Class Can't Change Argument
• J&J Hit With Class Suit Alleging FCRA Violations
• Ethicon Says Bulk Demand For Mesh Records Is 'Burdensome'
• Trends In Responsible Corporate Officer Doctrine Under FDCA
• Jaw Disease Patient's Novartis Suit Timely, 9th Circ. Hears
• Novartis Jaw Injury Suit Years Too Late, Judge Says
• Calif. Woman Wins Almost $10M In Ethicon Stapler Suit
• FDA Approves Genentech's Advanced Lung Cancer Drug
• 6th Circ. Cements J&J Win In Ortho Evra Blood Clot Suit
• FTC Asks Walgreens, Rite Aid For Info On $17.2B Merger
• Deals Rumor Mill: Pharmaceutical Product, GoPro, Quartz
• Give Judges Free Hand To Hike Patent Awards, Justices Told
• Steris Loss Won't Change FTC Merger Tactic, Ex-Official Says
• Celgene, Astellas Sue Teva Over Cancer Drug Patents
• AbbVie Targets Dr. Reddy's In Testosterone Gel Patent Suit
• Creditors Fight SIGA's Bid To Maintain Control Of Ch. 11
• J&J Found Liable In 3rd Risperdal Breast-Growth Case
• Texan Says 3M Device Led to Infection, Amputation
• Will Changes To Federal Rules Reduce Scope Of Discovery?
• A Closer Look At Ariosa After Fed. Circ. Denies Rehearing
• TriReme Loses $4.7M Fee Bid After Heart Catheter Trial Win
• Philly Jury Urged To Find Against J&J In Breast-Growth Case
• Jury Clears Ga. Man Of Insider Trading In Sanofi Case
• AstraZeneca Says Amneal Infringed Diabetes Drug Patents
• Biotech Wants Answers On Ex-GC's Role In Securities Scheme
• Gilead Pushes Court To Invalidate 2 Merck Drug Patents
• 2 Life Science Cos. Pull IPOs Over Weak Market Conditions
• DC Circ. Tosses Watson's Appeal Of Vascepa FDA Remand
• The Art Of The Mock
• Apotex Biosimilar Notice To Amgen Is Mandatory, Judge Says
• Drug Cos. Ask Court To Delay Decision Over Aggrenox Market
• Faster Generics Approval Could Cut Drug Costs, Senate Told
• Chancery Cuts Attys' Fees In Celgene Director Pay Deal
• Patents Not Sunk By Invalidation Of Some Claims, Judge Says
• PTAB Urged To Nix Reviews Sought By Bass-Affiliated Group
• Wholesale Drug Distributor Charged In $100M Fraud Scheme
• Baker & McKenzie Adds IP Litigator From Ropes & Gray
• AstraZeneca, Palmetto End Crestor Patent Fight
• Bass Loses Bid To Nix 'Ridiculous' Arthritis Drug Patent
• Strategies For Your Evolving Law Department
• CORRECTED: Teva Copaxone Patent Upheld As Valid By EPO
• Supplement Co. In Wal-Mart False Ad Row Wants Sanctions
• FDA Warning Wire: 'Life-Threatening' Compounder Supplies
• FedEx Wants To Know Drug Shipping Grand Jury Instructions
• Consumers Push For Judgment In Muscle Milk Ad Suit
• Del. Co. In Default In Pharma Dispute With Swiss Co.
• Judge Recuses Self In Suit Over DePuy Pinnacle Hip Implant
• Orthofix Reaches $11M Settlement in Securities Action
• Takeda, AstraZeneca Sue Apotex Over Generic COPD Drug
• The Unfortunate Fall Of The IPXI Marketplace
• GCs Love These Firms More And More
• Takeda Asks 9th Circ. To Act Before Tribal Trial In Actos Suit
• GCs Name Most Arrogant Law Firms
• 5 Firms Make It Back Onto GCs' Most Adored List
• 3 Firms Know The Secret To Keeping Clients Happy
• Specialty Pharmacy Can't Keep Express Scripts Contract
• Arbitration Required In $6M Breach Suit, Pharma Co. Says
• Fed. Circ. Urged To Revive 'Inventive' DNA Patent
• Judge Postpones Stent IP Trial Between WL Gore and CR Bard
• Illumina Urges Fed. Circ. To Reinstate Sequencing Patent
• Ethicon Official In Pa. Mesh Trial Defends Product's Safety
• False Claim Not Apparent To 2nd Circ. In Lipitor Suit
• All Camps Agree: Memorable Biosimilar Names Are A Must
• AstraZeneca, Others Must Expand Diabetes Drug Warnings
• Where Common Law Litigation And Int'l Arbitration Divide
• Girardi Keese Asks Justices To Nix $10M Avandia Fee Sharing
• 6th Circ. Vacates Ex-Atty's Sentence Over Fen-Phen Fraud
• Galena To Pay $20M To End Investor Suits Over Deceptive PR
• Ethicon Safety Commitment Questioned In Pa. Mesh Trial
• Unions Tell Obama That TPP Will Lower Living Standards
• St. Jude Gets Wireless Communications Patent Claims Nixed
• AbbVie, Endo Deceived Men About Testosterone Gel, Suit Says
• Brazil Raids Medical Device Cos. On Antitrust Worries
• UCB Awarded $6M In Fees In Apotex Infringement Suit
• AbbVie Sues Sandoz Over Testosterone Gel Patents
• Taxation With Representation: Wachtell, Skadden, Latham
• Quick Win For Drug Cos. Unlikely In Testosterone Therapy MDL
• J&J Says Mother's Testimony Not Worth $2.5M Risperdal Award
• Mylan Latest To Feel DOJ Heat Over Generics Price Hikes
• Pfizer Seeks To Toss Zoloft Birth Defects MDL
• Perfect Surgical Asks Fed. Circ. To Revive Claims On 2 Patents
• 3 Takeaways From The DOJ's $3.6B FCA Haul
• Senate Votes To Repeal Key ACA Provisions
• Gore Stent Graft Patents' Validity, Definiteness Upheld
• Medtronic Crushes Lenox Bone Mill Antitrust Row
• Deals Rumor Mill: Staples, Royal Dutch Shell, Teva
• FDA Pushes Final Generic Labeling Rule To July
• 5 Tips To Avoid Spoliation Sanctions
• Ill.'s Medicaid Prescription Cap Challenged In 7th Circ.
• AstraZeneca Defends NJ Venue In Breast Cancer Drug Row
• Life Sciences MVP: White & Case's Jack Pace
• XBiotech Faces Class Action Over Drug Study Problems
• Pfizer Wins Exclusion Of Zoloft Birth Defect Testimony
• The Unrealized Promise Of Rule 26 Amendments
• Bayer Gets 10 Cases Tossed From Mirena Defect MDL
• Fed Circ. Affirms Nixing Of Claims In Hill-Rom's Bed Patent
• Ethicon Can't Duck Patients' Defect Claims In Mesh MDL
• How GlaxoSmithKline Forced Its Firms To Think Differently
• Boston Scientific, Bard Must Pay For Mesh Injury, Jury Told
• Life Sciences MVP: Sullivan's Krishna Veeraraghavan
• FDA Orders Dietary Products Pulled Over Synthetic Drug
• Investor Classes Certified In SAC Capital Insider Trading Suit
• Mass Tort Status Sought For Cipro, Avelox, Levaquin Cases
• White House Threatens Veto Of ACA Repeal Bill
• GNC Facing Another Class Action Over 'Spiked' Supplements
• Pelvic Mesh Caused Irreversible Conditions, Pa. Jury Hears
• IP Firm Wolf Greenfield Adds Ex-Locke Lord Atty As Partner
• What To Expect From HHS Inspector General Next Year
• Full Fed. Circ. Won't Rehear Fetal DNA Patent Row
• FDA Warning Wire: Nvision, Compounders, Drugged Meat
• Senate Forges Ahead With Effort To Repeal ACA
• Sens. Unveil Huge Stash Of Gilead Drug-Pricing Records
• Lupin Says 'Sensitive' Docs Are Irrelevant In Paxil Fight
• Homeopathic Co. Says Evidence Still Missing In False Ad Suit
• Life Sciences MVP: Sullivan & Cromwell's Matt Hurd
• Montel-Endorsed Apparel Co. Settles FTC Suit For $1.4M
• Glaucoma Drug Co. Says Investor Suit 'Makes No Sense'
• Bass, Spangenberg Target Diprivan Patent In AIA Review
• A Close Look At The Latest Anti-Inversion Guidance
• Defending 'Salt Patents' In Hatch-Waxman Cases
• Making The Most Of Document Analytics